Heterogeneity of ERBB2 in gastric carcinomas: A study of tissue microarray and matched primary and metastatic carcinomas

Modern Pathology

Volumn 26, Issue 5, 2013, Pages 677-684

  Yoon Cho, Eun ^a   Park, Kyeongmee ^b   Do, Ingu ^c   Cho, Junhun ^a   Kim, Jiyun ^a   Lee, Jeeyun ^c   Kim, Seonwoo ^a   Kim, Kyoung Mee ^a   Sung Sohn, Tae ^a   Ki Kang, Won ^c   Kim, Sung ^a  

^a Samsung Medical Center   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Amplification; ERBB2; gastric; immunohistochemistry; metastatic; primary

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; SILVER; TRASTUZUMAB;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CLINICAL TRIAL; COMPARATIVE STUDY; DISTANT METASTASIS; FEMALE; GASTRECTOMY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; TISSUE MICROARRAY;

EID: 84877033918     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.205     Document Type: Article

References (38)

1. Samanta A, LeVea CM, Dougall WC, et al. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci USA 1994;91:1711-1715.
2. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-1052.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
4. Song Y, Huang J, Wang JW. Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma. Ai Zheng 2010;29:76-81.
5. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991;51:1034-1038.
6. Roh JK, Paik S, Chung HC, et al. Overexpression of erbB-protein in gastric adenocarcinoma-a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. Gan To Kagaku Ryoho 1992;19:1207-1219.
7. Yonemura Y, Ninomiya I, Ohoyama S, et al. Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer. Oncology 1992;49:363-367.
8. UchinoS,TsudaH,MaruyamaK, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993;72:3179-3184.
9. Lee HR, Kim JH, Uhm HD, et al. Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 1996;53:192-197.
10. Shun CT, Wu MS, Lin JT, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 1997;44:604-609.
11. Wu MS, Shun CT, Wang HP, et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1997;112:1457-1465.
12. Allgayer H, Babic R, Gruetzner KU, et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000;18:2201-2209.
13. Sanz-Ortega J, Steinberg SM, Moro E, et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 2000;15:455-462.
14. Wang YL, Sheu BS, Yang HB, et al. Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma-emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology 2002;49:1172-1176.
15. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002;98:833-837.
16. Pinto-de-Sousa J, David L, Almeida R, et al. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002;10:247-256.
17. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-1379.
18. Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-2118.
19. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009;135:1331-1339.
20. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-777.
21. Hoang MP, Sahin AA, Ordonez NG, et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-859.
22. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9:R31 2007.
23. Santinelli A, Pisa E, Stramazzotti D, et al. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122:999-1004.
24. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
25. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-1529.
26. Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011;59:822-831.
27. Cho EY, Srivastava A, Park K, et al. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 2012;44:216-220.
28. Sobin LGM, Wittekind C eds. TNM Classification of Malignant Tumours 7th edn. International Union Against Cancer (UICC): New York, Wiley, 2009.
29. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
30. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
31. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-650.
32. Morris MJ, Reuter VE, Kelly WK, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002; 94:980-986.
33. Jimenez RE, Hussain M, Bianco FJ Jr., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440-2447.
34. Edgerton SM, Moore D 2nd, Merkel D, et al. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11:214-221.
35. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57-65.
36. Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990;50:8002-8009.
37. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and realtime quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393.
38. Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487-493.